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Computer-aided 3D printing approaches to the industrial production of customized 3D 
functional living constructs for restoration of tissue and organ function face significant 
regulatory challenges. Using the manufacture of a customized, 3D-bioprinted nasal 
implant as a well-informed but hypothetical exemplar, we examine how these products 
might be regulated. Existing EU and USA regulatory frameworks do not account for 
the differences between 3D printing and conventional manufacturing methods or the 
ability to create individual customized products using mechanized rather than craft 
approaches. Already subject to extensive regulatory control, issues related to control 
of the computer-aided design to manufacture process and the associated software 
system chain present additional scientific and regulatory challenges for manufacturers 
of these complex 3D-bioprinted advanced combination products.
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Worldwide, groups are increasingly turning 
their attention to additive manufacturing or 
3D printing technologies and approaches to 
fabricate 3D medicinal products and devices. 
These range from relatively simple custom-
ized implants or prosthetics printed from 
single metals or polymers, to 3D-cell-based, 
functional living constructs with biological 
and mechanical properties suitable for clini-
cal restoration of tissue and organ function 
at increasing levels of complexity [1–4]. How-
ever, despite recent significant and exciting 
scientific and medical advances, the indus-
trialization of these 3D-printed customizable 
medicinal products faces notable regulatory 
challenges under existing frameworks.
Working with a leading ear, nose and 
throat consultant, the multidisciplinary team 
within the Centre for Innovative Manufac-
turing in Regenerative Medicine at Notting-
ham University is developing a 3D-printing 
process for the production of a prosthetic 
implant for the total replacement of the nose 
following oromaxillary nasal trauma after 
tumor removal. Using thermoresponsive 
materials and a new 3D-printing platform, 
the implant can be printed from a 3D image 
of the patient’s original nose or other alterna-
tive, providing a strong, weightbearing and 
novel noncontracting biofabricated scaffold 
incorporating precisely positioned autolo-
gous cells. As part of a collaborative project 
with researchers at Nottingham University, 
we have used this well-informed but hypo-
thetical exemplar of a 3D functional living 
construct to investigate the regulatory chal-
lenges posed by 3D-bioprinting and its abil-
ity to create customized cell-scaffold prod-
ucts, which are personalized by geometry 
and constituent cells.
To determine which Regulations or Direc-
tives may apply, we first examine the legis-
lation which describes the frameworks that 
regulate advanced combination of medicinal 
products in the EU and the USA. Broadly 
defined as products comprising two or more 
regulated components, we examine the fac-
tors influencing their classification and map 
the emerging regulatory landscape to illus-
trate the key principles and processes for 
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their premarket review, authorization and postmarket 
regulation. Next, we use this case example to shed light 
on the key scientific and regulatory challenges that 
may have significant ramifications under the existing 
legislation for manufacturers intending to apply com-
puter-aided 3D-bioprinting approaches to the manu-
facture and industrial production of these complex, 
customized 3D products.
The intent is to provide evidence of general appli-
cability to products with similar characteristics and a 
framework to elucidate the criteria for establishing the 
regulatory readiness of the 3D-printing technology 
when tested against current and emerging regulatory 
frameworks in the EU and the USA. This is now being 
recognized by important stakeholders as a likely bar-
rier to their clinical use. The test case example takes 
the regulatory viewpoint from the perspective of a 
manufacturer making and assembling both the cellu-
lar and scaffold component parts in the same produc-
tion facility using an industrial process (note: there is 
no clear regulatory definition for an ‘industrial process’ 
by which the advanced therapy medicinal product 
(ATMP) regulation attempts to distinguish commercial 
enterprise from ‘hospital’-based preparation of therapies 
for single patients on a one-off basis). The case does not 
cover distributed manufacturing strategies or product 
development pathways under fast track approval pro-
grams (USA) or named patient and hospital exemp-
tion (EU) regulatory schemes, although these are also 
anticipated to raise other regulatory issues for the tech-
nology. The purpose of this distinction is to examine 
the changes necessary within the existing regulations if 
such products are to reach patients on the scale required 
to achieve their full potential for patient well-being.
Methodology
The contents and coverage of the EU and USA legal 
frameworks for the regulation of therapeutic products 
intended for human use were analyzed to identify the 
applicable medicinal product categories and which 
of the legal instruments and associated guidelines 
included combined medicinal products. Characteris-
tics and features critical for determining the regulatory 
classification of cell-based medicinal products were 
identified. The legislation was reviewed using associ-
ated guidelines and standards to interpret the provi-
sions of the requirements in the development process 
and identify the regulatory input across each stage of 
the product development pathway.
Classification of medicinal products under 
EU & USA regulatory frameworks
The rules governing the placement of human medi-
cines on the market in the EU and the USA are broadly 
divided under public health and core pharmaceuti-
cal and medical device legislation. Pharmaceuticals, 
biologics and medical devices are subject to different 
regulatory requirements that govern premarket applica-
tions, manufacturing practices and postmarket report-
ing of adverse events. In the USA, the Code of Federal 
Regulations (Title 21 CFR), based on the Federal Food, 
Drug and Cosmetic Act (FD&C Act) and the Public 
Health Service Act (PHS Act), establishes the legal 
framework within which the US FDA regulates the 
distribution and sale of medical products. These legal 
instruments provide the precise product definition and 
legal basis for classification of products as drugs, bio-
logics, medical devices or combination products. Each 
of the product types is regulated by a different office 
within the FDA, either the Center for Drug Evaluation 
and Research (CDER), the Center for Biologics Evalu-
ation and Research (CBER) or the Center for Devices 
and Radiological Health (CDRH). In the EU, a rele-
vant product can only be regulated as either a medicinal 
product (whether drug or biologic) or a medical device, 
as classified by the applicable and legally separate sector-
specific legislation that differ markedly in terms of pro-
cedures to be followed to place the product on the EU 
market. In broad terms, this legislation is enacted by 
the EMA under EU regulations and a number of legally 
binding directives that are addressed to the National 
Competent Authorities (NCA) of the member states.
However, while the principal definitions in the EU 
and USA legislation have set out the key elements in 
characterizing medicinal products as single entities 
with respect to the presentational (properties related 
to intended use) and the functional aspects, the emer-
gence of ever more sophisticated products and medical 
approaches continues to challenge the existing demar-
cation between these regulated product categories. For 
manufacturers and regulators of products which com-
bine components or show features from more than one 
of these product categories this has made the classifica-
tion process increasingly more complex. Understand-
ing how these combination products fit the existing 
regulatory frameworks from the earliest stage of devel-
opment will be crucial to unlocking the potential clini-
cal advantages of the technologies. It will help manu-
facturers determine the applicable regulatory pathway 
and identify the appropriate product development 
strategy and risk management plans for navigating the 
route to their intended geographical market(s).
How are cell-scaffold combination products 
regulated?
In the USA, combination products as legally defined 
entities under 21 CFR 3.2(e) [5], are broadly regulated 
by the FDA as products comprising two or more regu-
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lated components (i.e., drug–device, device–biologic, 
drug–biologic or drug–device–biologic) that are physi-
cally, chemically or otherwise combined or mixed and 
produced as a single entity. As defined, the term also 
includes components that are co-packaged or pack-
aged separately but have labeling that requires use with 
another component to achieve the intended use (not 
relevant to this test case example). In the EU however, 
there is no general definition or specific regulation for 
a combination product. As a general rule, combination 
products are currently regulated in the EU as medicinal 
products (including ATMPs) or medical devices under 
the respective sector-specific legislation [6,7]. Classifica-
tion remains an area of discussion at the European level 
with recent publications on the classification of ATMPs 
and borderline products [8,9].
For a combination product that consists of or con-
tains cells or tissues and a scaffold matrix, the classifi-
cation and thus the legislation into which the product 
fits is determined by the way in which the finished 
product achieves its intended medical purpose, the 
claimed mode of action (MoA), the characteristics of 
the active substance and the way in which it is com-
bined in the finished product. This means the manu-
facturer would need to determine a number of critical 
characteristics that define the product under develop-
ment before being able to classify the finished product 
as follows:
•	 Does the cellular or tissue part of the product meet 
the definition of a biological medicinal product as 
defined in Directive 2001/83/EC (EU) [6] or the 
definition of a Human Cells, Tissues, and Cellular 
and Tissue-Based Product (HCT/P) under 21 CFR 
1271(US) [10]?
•	 If so, is the cellular or tissue part presented has 
having properties liable to act on the human body 
when combined with the scaffold/matrix?
•	 Does the scaffold/matrix form an integral part of 
the finished product?
•	 How is the finished product (i.e., ready for clinical 
use) intended to function/work in the recipient?
•	 How is the principal/primary intended MoA of the 
finished product achieved?
This five-step question framework provides the basis 
for analyzing the features of the product and process 
that influence the classification of the 3D-bioprinted 
cell-scaffold nasal implant and how this dictates the 
regulatory input into the development process for such 
cell-based combination products under EU and USA 
regulatory frameworks.
Features influencing the classification 
& regulatory governance of the 
3D-bioprinted nasal implant
The manufacturing process for the centralized indus-
trial production of the autologous 3D-bioprinted nasal 
implant product is shown in Figure 1. The figure shows 
a cross-functional map of the whole production process 
envisaged for the manufacture of the active substance 
and the finished product, where the manufacturer, 
as the holder of the manufacturing authorization (as 
defined in Article 40 of Directive 2001/83/EC) [6], is 
making both component parts in the same production 
facility. In identifying the major processing steps and 
process flows involved from biopsy to patient delivery, 
the map provides the basis for determining where the 
regulatory legislation and associated scientific guid-
ance might apply across each stage of the development 
pathway (as indicated by the swim-lanes).
The process begins with surgical retrieval of a 
patient biopsy sample from autologous ear and rib 
cartilage, harvested under local anesthesia in the pri-
mary care facility. Once acquired, the tissue sample, 
which represents the source of autologous chondrocyte 
cells, is transported to the facility of the manufacturer 
for processing under Good Manufacturing Practice 
(GMP). On arriving at the facility, the tissue is trans-
ferred to a highly controlled environment (Grade A 
or Class 100) for further processing. The cells are 
isolated from the biopsy tissue and expanded ex vivo 
for several weeks to achieve the required numbers of 
clinically relevant cells in 2D monolayer culture. In an 
industrialized manufacturing process, the expanded 
live cells are encapsulated within a UV cured synthetic 
gelatin methacrylate (GelMA) hydrogel (as an example 
of an available ‘printable’ and biocompatible synthetic 
polymer). Under a Grade A environment, the cell-
laden hydrogel is co-printed with a clinically approved 
(i.e., used in CE marked, surgically deployed devices) 
biodegradable polycaprolactone (PCL) matrix using 
a commercially available, computer-aided bioprinting 
system (regenHu 3D-printer) via a two-stage process.
Broadly described, image data derived from com-
puted tomography (CT) scans or magnetic resonance 
imaging (MRI) of the patient’s nose is transformed 
(software segmentation) using computer-aided design 
(CAD) software into an accurate digital 3D model 
of the nose. Machining process templates are used to 
automatically apply predefined programming meth-
ods, setups, machining operations and tool selections 
to new patient cases. At this stage, computer-aided 
manufacturing (CAM) software is used to automati-
cally update the shape definitions and other customiza-
tion features (e.g., stiffness and diffusion properties) 
of the implant according to the surgeon’s specification 
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(the surgical plan), thereby tailoring the implant to 
individual patient requirements. The 3D-printing 
machine then assembles the cell-laden hydrogel and 
PCL components into the finished (or intermediate) 
cell-scaffold product.
Postproduction, the tissue construct is maintained 
in vitro in a perfusion bioreactor to allow time for 
cell-mediated cartilage extracellular matrix (ECM) 
remodeling (e.g., collagen and fibrous protein produc-
tion; [11]) and maturation toward a solid construct (and 
potentially patient-matched testing pre-implantation) 
before transfer back to the primary care facility for 
implantation into the same patient. Alternatively it 
may be remodeled intraoperatively and matured in situ 
once implanted into the patient and begins to integrate 
with existing bone. The reconstructive surgical step 
is likely to include final shaping and suturing by the 
surgeon and the use of pedicle flaps to re-establish ade-
quate tissue perfusion to the implant postoperatively to 
permit further remodeling and integration.
The following sections will explore these product 
and process features as they relate to how the EMA and 
the FDA might regulate these cell-based combination 
products in the EU and the USA, respectively.
The EMA’s approach to regulating 
combination products in the EU
Classification & premarket review
Considering the properties and MoA of the individual 
cellular and other material parts and the way in which 
these as distinct components are combined in this case 
example, Figure 1 shows that autologous cartilage tissue 
derived chondrocyte cells are expanded ex vivo in cul-
ture before being co-printed as living cells with a syn-
thetic scaffold matrix to form the finished product for 
use in humans. Under EU legislation, where the prod-
uct contains viable cells or tissues, the pharmacological, 
immunological or metabolic action of these cells is con-
sidered to be the principal MoA. The cells are intended 
to be used for the same essential function (homolo-
gous use) but as expanded cells they are considered to 
be substantially manipulated according to annex 1 of 
the ATMP Regulation (EC) No 1394/2007 [15]. The 
derived living cellular part of the combination therefore 
qualifies as an active substance of a biological medicinal 
product according to EU Directive 2001/83/EC [6] and 
falls within the scope and additional provisions of the 
ATMP regulation [15].
For the substantially manipulated cellular part of 
the combination, provided it is not genetically modi-
fied as defined under Directive 2001/83/EC [6], the 
specific requirements for somatic cell therapy medici-
nal products (sCTMP) under Directive 2001/83/
EC [6] or tissue-engineered products (TEP) under 
Regulation (EC) No 1394/2007 [15] apply. The deci-
sion on whether a product fulfills the requirements 
of an sCTMP or a TEP is taken on the basis of the 
principal MoA and the intended function claimed by 
the manufacturer. In this context, it is important to 
ascertain whether the product is for treatment, preven-
tion or diagnosis of a disease and exerts its activity via 
a pharmacological, immunological or metabolic action 
or whether the intended MoA of the product is regen-
eration, repair or replacement of cells/tissues. In this 
case example, the principal MoA is provided by the 
viable chondrocyte cells, linked to inducing the regen-
eration of cartilage tissue at the site of implantation. 
According to the definition in Article 2(1)(b) of Regu-
lation (EC) No 1394/2007 [15], this would specifically 
qualify the product as a tissue engineered product.
In this instance, because the cells are combined with 
the synthetic scaffold matrix at the time of manufac-
ture and it retains its original form and function in the 
finished product, the scaffold is considered as a starting 
material and as an integral part of the finished prod-
uct [6]. Here, the principal function of the bioresorb-
able scaffold matrix is to provide a physical and per-
missive support for the attachment and growth of cells 
and to reproduce the required form and shape of the 
nose at the site of implantation. Tissue regeneration is 
accomplished by the living cells as the scaffold matrix 
undergoes progressive degradation while new tissue 
regenerates to replace missing cartilage. Referring to 
the EU definition of a medical device, this places the 
MoA for scaffold matrix firmly within the scope of the 
European medical device legislation [6,7,16,17].
This being the case, the candidate ATMP classifi-
cation can be identified. On the basis that the prod-
uct consists of substantially manipulated chondrocyte 
cells, is presented as having properties for regeneration 
and repair of a human tissue, and contains as an inte-
gral part, scaffold material that fulfills its function as 
a medical device when deployed in the patient, the 
product falls within the definition of a tissue engi-
neered combined ATMP, as defined in article 2(1)(d) 
of Regulation (EC) No 1394/2007/EC [15].
However, although it is important to get clarifica-
tion of the regulatory requirements as early as possible, 
in practice the manufacturer may not have sufficient 
data and/or scientific knowledge in the early devel-
opment stage to substantiate the principal MoA and 
thereby identify the candidate ATMP classification. 
As the underlying science improves, the manufac-
turer may need to clarify whether the product under 
development still meets the scientific criteria that 
define combined ATMPs so that questions of evolv-
ing borderlines between other noncombined ATMP 
categories and even non-ATMPs can be resolved [7,8]. 
www.futuremedicine.com 5future science group
Regulatory requirements for 3D bioprinting    Review
Figure 1. Cross-functional flow diagram of the manufacturing process for the centralized industrial production of a personalized 
autologous 3D-bioprinted combination product for total replacement of the nose after tumor removal. Cell culture and bioprinting 
activities are co-located in the Good Manufacturing Practice (GMP) manufacturing facility. The swim-lanes show the key activities and 
highlight transfer (red arrows) between the GMP manufacturing facility (unshaded swim-lanes) and the primary care facility (shaded 
swim-lanes). Blue boxes and arrows delineate activities involved in the computer-aided bioprinting process. The qualified person 
assesses release criteria and adherence to GMP/quality system regulation standards before release of the finished product batch. 
The starting materials, drug substance and drug product are defined according to both EMA and US FDA guidance documents [12,13]. 
These elements define the quality expectations for subsequent clinical trial and manufacturing authorization submissions [14]. 
CAD: Computer-aided design; CAM: Computer-aided manufacturing; CT: Computed tomography; PCL: Polycaprolactone.
System map for 3D bioprinting of autologous combination product 
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For instance, to make sure that the device part of the 
combination is acting as a device rather than an excipi-
ent or an active substance of the final product or to 
make sure the function of the matrix does not become 
decoupled from its structural properties at the time of 
implantation. The Committee for Advanced Therapies 
(CAT) provide scientific advice on whether a product 
meets the scientific criteria which defines ATMPs [18].
Once the candidate ATMP classification has been 
clarified and confirmed, the manufacturer will need to 
continue dialogue with the CAT as processes and pro-
cess knowledge evolve between the research and indus-
trialization stages. To build a robust regulatory strategy 
and a postapproval change management plan, the man-
ufacturer will need to anticipate process changes and 
consider long-term plans for transfer of the discovery or 
pilot processes to clinical-grade GMP production. For 
instance, plans that involve modification to the manu-
facturing process or changes to product composition, 
such as changes to the source and/or level and type 
of manipulation of the starting material, the type and 
characteristics of the biomaterial (new or novel material 
is likely to require Class III regulatory approval), use 
of additional cellular material or addition of adjuncts, 
such as growth factors or antibodies that enhance cell 
attachment for example, will all raise similar questions 
with regard to borderline status and ultimately impact 
the regulatory classification decision.
From an EU perspective, an ATMP which comprises 
an integral combination of a medical device, as defined 
in Directive 90/385/EEC [16] or 93/42/EEC [17] (both 
amended by Directive 2007/47/EC), and a cellular 
part in which the cells are viable (or are exclusively 
nonviable but with an action that is primary to that 
of the device part), is regulated as a combined ATMP 
under Directive 2001/83/EC and Regulation (EC) 
No 1394/2007 [6,15]. According to the procedural 
advice on the evaluation of combined ATMPs’ [19], the 
product as a whole is subject to evaluation by the CAT 
and centralized market authorization by the EMA in 
accordance with the provisions of Regulation (EC) 
No 726/2004 [20]. As a starting material, combined 
as an integral part with the manipulated cells, the 
device part (and/or associated packaging and instruc-
tion leaflets) should be CE marked for the intended 
use (issued by the Notified Body (NB); a certifica-
tion organization designated by the NCA to carry out 
the conformity assessment procedures) or it should 
conform to the Essential Requirements laid down in 
Directive 2007/47/EC (the amending medical device 
legislation) [7]. This information is required as part of 
the market authorization application (MAA), which 
will include information on the intended function of 
the medical device and demonstration of compatibility 
of the device with other components of the product. 
Where available this would also need to include the 
results of an assessment of the medical device part of 
the combined ATMP by the NB in accordance with 
the medical devices legislation. If not, the EMA will 
seek an assessment from the NB unless the CAT 
advises otherwise.
The national and centralized provisions under this 
core ATMP legislation, in addition to the relevant med-
ical device Directives, form the regulatory framework 
that controls all critical aspects of the development, 
manufacture, approval and subsequent postmarket 
vigilance for combination ATMPs. This includes regu-
latory input into setting the quality and safety stan-
dards for donation, procurement and testing of human 
cells or tissues under the EU Tissue and Cells Directive 
(Directives 2004/23/EC, 2006/17/EC and 2006/86/
EC). This also includes standards for the manufacture 
of products in compliance with the principles of GMP 
(Directive 2003/94/EC; Eudralex Volume 4) and for 
conduct of clinical trials in the EU (Directive 2001/20/
EC) in accordance with the principles for Good Clini-
cal Practice (GCP) laid down in Directives 2005/28/
EC and 95/46/EC [21]. Summarized in Figure 2, this 
legislative framework provides clarity on the EU Regu-
lations and Directives that should be applied at each 
stage of the combination ATMP development path-
way. From a scientific perspective, technical guidance 
documents have been issued and interaction platforms 
are available to define and make this EU regulatory 
framework more accessible (see Eudralex website, [57]). 
Recognizing combination ATMPs as a distinct prod-
uct category, the CAT has issued specific procedural 
advice for their classification and evaluation [18,19] but 
little specific guidance is currently available other than 
that incorporated in the general cell-based medicinal 
product or ATMP guidelines [12,15]. For the medi-
cal device part, national and international standards 
will play a much more significant function in demon-
strating compliance with the Essential Requirements 
defined in the medical device Directives [22].
The FDA’s approach to regulating 
combination products in the USA
Classification & premarket review
In the USA, as a product containing living human 
cells that are intended for implantation or transplanta-
tion into a human recipient as part of a synthetic scaf-
fold matrix, the cellular part qualifies as an HCT/P, 
as defined in 21 CFR Part 1271.3(d) [10]. In this case 
example, as more-than-minimally manipulated cells 
(as defined in 21 CFR Part 1271.1(f)), the derived cel-
lular part of the product falls within the scope of the 
biologics regulation under Section 351 of the PHS Act 
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Figure 2. Summary of the main EU and US regulatory legislation for a combination product that comprises an integral combination 
of a medical device (scaffold) and a cellular part consisting of viable substantially manipulated cells. The figure indicates which 
legislation applies at each development stage, using a specific synthetic 3D-bioprinted cell-scaffold nasal implant product as a 
case example. The legislation may overlap stages for example between the legislation identified for cell processing and that for 
GMP manufacture. In EU, manufacturers must demonstrate compliance with applicable regulation/directives for advanced therapy 
medicinal products (ATMPs) and medical devices. The manufacture of products regulated as an ATMP is authorized by the National 
Competent Authorities of the Member State concerned. For clinical trials occurring within their borders, the remit of the National 
Competent Authorities also includes assessment of applications for clinical trial authorization and the associated manufacturer’s 
license for investigational ATMPs, noting that a new EU Clinical Trials Regulation No 536/2014 becomes applicable in 2016 to replace 
Directive 2001/20/EC. The pharmacovigilance guidance for human medicinal products (Eudralex Volume 9A) is replaced by the Good 
Pharmacovigilance Practice (GMP) guidelines released by the EMA [23], but until the availability of the respective GMP modules, 
Eudralex Volume 9A remains the reference [24]. All EU Directives and Regulations (as amended) can be accessed via the Eudralex 
website [57]. In the USA, the US FDA is responsible for all facets of regulating combination products. The FDA provides an option 
for a streamlined hybrid approach to GMP compliance and postmarket reporting when both constituent parts are manufactured 
at the same facility. This determines which CFRs apply – provisions for manufacturers following CFR 820 and/or CFR 210/211. All US 
Regulations can be accessed via the FDA website [58]. 
Key: **: amending Medical Device Directive; Light blue swim-lane: applicable EU ATMP directives and regulations; Red swim-
lane: applicable US CFRs; Yellow boxes: applicable Medical Device Directives or Regulations applicable to combination products; Grey 
boxes: specific US regulations applied to combination products. 
BLA: Biologics License Application; CFR: Code of Federal Regulation; GCP: Good Clinical Practice; GMP: Good Manufacturing Practice; 
GTP: Good Tissue Practice; IND: Investigational New Drug; MAA: Market authorization application.
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and 21 CFR Part 1271 [10]. The manipulated living 
cells are physically combined with the synthetic scaf-
fold matrix to create a finished product with a medi-
cal purpose. As defined in Section 201(h) of the FDC 
Act, the function of the clinically approved (i.e. used in 
FDA approved, surgically deployed devices) bioresorb-
able scaffold matrix places it firmly within the scope of 
the USA medical device legislation (primarily under 
applicable parts of 21 CFR 800-898).
Under the USA regulatory system, a biologic prod-
uct which is physically combined with an integral con-
stituent part that would independently be regulated 
as a medical device and produced as a single entity is 
defined as a combination product under 21 CFR 3.2(e) 
[5]. In accordance with Section 503(g) of the FD&C 
Act (21USC 353(g)) the FDA (via the Office of Com-
bination Products; OCP) classifies these combination 
products according to the primary MoA through which 
the product achieves its therapeutic effect. This is simi-
lar to the situation in the EU, but in this case deter-
mines which of the CBER, the CDER or the CDRH 
will lead the premarket review process and determine 
the regulatory pathway most appropriate for the prod-
uct. Under 21 CFR 3.7 [5], by submitting a ‘Request 
for Designation’ (RFD) to the OCP, the manufacturer 
can obtain a formal determination of the combination 
product’s primary MoA and identify the lead agency 
Center assigned to the product’s premarket review and 
postmarket regulation. In the case of the nasal implant, 
the FDA would assign the product to the CBER as the 
lead agency because the cellular constituent part (the 
HCT/P component) provides the greater contribution 
to the overall therapeutic effect of the combined prod-
uct, as previously described. The product would there-
fore be regulated as an HCT/P within the scope of the 
biologics legislation under Section 351 of the PHS Act 
and 21 CFR 1271 [10]. Based on an assessment of the 
safety and effectiveness of the constituent parts and 
their interaction, the product would be reviewed under 
a single Biologics License Application (BLA) in accor-
dance with the provisions set out in 21 CFR parts 600, 
601 and 610 [25–27].
This core legislation forms the regulatory framework 
that the FDA uses to control all critical aspects of the 
development, manufacture, approval and subsequent 
postmarket vigilance for biologic-device combination 
products. This includes regulatory input into setting 
the quality and safety standards for donation, procure-
ment and testing of human cells or tissues under GTP 
(21 CFR 1271). This also includes standards for the 
manufacture of HCT/Ps in compliance with the prin-
ciples of GMP (21 CFR 210/211) and for conduct of 
clinical trials in the USA via an Investigational New 
Drug (IND) application under 21 CFR 312 and in 
accordance with the principles for GCP laid down in 
21 CFR parts 11, 50, 54 and 56 [21]. Summarized in 
Figure 2, this legislative framework provides clarity on 
the USA regulations that should be applied at each stage 
of a biologic-device combination product development 
pathway. The FDA has issued multiple technical guid-
ance documents to help guide HCT/P manufacturers 
and define the US regulatory framework (see FDA web-
site). Unlike the EMA, the FDA under a more general 
definition (21 CFR 3.2(e); [5]) identifies combination 
products as a distinct category of product that could be 
subject specialized regulatory controls. To that effect the 
FDA has issued or proposed new rules aimed at provid-
ing greater clarity on how current GMP and postmarket 
safety reporting requirements are applied to combina-
tion products. Their implementation has implications 
for manufacturers of biologic/device combination 
products intended for distribution and sale in the USA.
Good Manufacturing Practice & Quality System 
requirements for combination products under 
EU & US regulatory frameworks
The final rule on cGMP requirements for combi-
nation products was implemented by the FDA in 
July 2014 [28,29]. As defined under 21 CFR 4 (Subpart A), 
the rule applies to all ‘single-entity’ and ‘co-packaged’ 
combination products, including legacy products 
already being manufactured prior to the rule’s effective 
date. Under the final rule, as part of their compliance 
with cGMP, a manufacturer of single entity combina-
tion products comprising both an HCT/P and a medi-
cal device has two options for demonstrating compli-
ance with applicable quality system requirements. The 
manufacturer could demonstrate compliance with each 
applicable regulation in its entirety by implementing a 
quality system that fully incorporates the cGMP regu-
lations under 21 CFR 210/211 [30,31] and the device 
Quality System Regulations (QSR) in 21 CFR 820 
(Figure 2) [32]. Alternatively, the manufacturer could 
elect to follow a ‘streamlined approach’. This allows 
operational compliance with either 21 CFR 210/211 or 
21 CFR 820 rather than both, provided that they also 
incorporate a specified subset of provisions from the 
other GMP framework (Box 1).
For example, as a single entity combination product 
comprising an HCT/P and a medical device, the man-
ufacturer of the nasal implant operating in compliance 
with 21 CFR 210/211, would also be required to incor-
porate the applicable provisions from 21 CFR 820, 
as specified in Box 1. They would also need to dem-
onstrate compliance with the relevant provisions of 
21 CFR 600-680 and 21 CFR 1271 (Figure 2) [33]. This 
‘streamlined approach’ is only available when both 
the HCT/P and device constituent parts are being 
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manufactured at the same facility.
Under the existing regulatory frameworks in the EU, 
when both the ATMP and medical device constituent 
parts are being manufactured at the same facility, the 
manufacturer is required to demonstrate compliance 
with each applicable regulation. The manufacturer 
must apply for assessment of the quality system (estab-
lished under ISO13485 for example; [34]) with the NB 
under Annex II and V of Directive 93/42/EEC [17]. 
The manufacturer is required to operate in compliance 
with the principles of GMP for medicinal products laid 
down in Directive 2003/94/EC [35] and Annex 2 of the 
EU GMP guidelines [36], in addition to the relevant 
provisions of Article 5 of the ATMP Regulation (EC) 
No 1394/2007 (Figure 2) [15].
Post-authorization vigilance systems for 
combination products under EU & USA 
regulatory frameworks
In 2015, the FDA is set to issue a final rule to clarify the 
postmarket safety reporting requirements for combina-
tion products. The rule will create Subpart B of 21 CFR 
Part 4 [37]. Intended to minimize duplicative reporting 
requirements, it will clarify that a combination prod-
uct is subject to the reporting requirements associated 
with the type of MAA under which the product was 
approved or licensed and to certain additional require-
ments dependent on the type of constituent parts of 
which it is comprised. For example, the developer of a 
biologic/device combination product approved under 
a BLA would be subject to the postmarket adverse 
event reporting requirements for biological products 
under 21 CFR 314.80(c) and 600.80(c), but may also 
be required to comply with the device requirements 
should an adverse event occur that is attributable to 
the device constituent part under 21 CFR. 803.20 or 
21 CFR 803.53(a) (Figure 2) [23,38,39].
In the EU, the manufacturer of a combination 
ATMP authorized through the centralized procedure 
would be subject to the postmarket reporting require-
ments for both the ATMP and the medical device 
constituent parts should an adverse event occurs. 
The combination ATMP would be subject to com-
mon rules for postauthorization surveillance (phar-
macovigilance) of medicinal products for human use 
under Directive 2012/26/EU and Regulation (EU) No 
1027/2012, in addition to the provisions of Regulation 
(EC) No 1394/2007 (Figure 2) [15,40,41]. The combina-
tion ATMP would also be subject to the medical device 
vigilance system requirements contained within Direc-
tive 2007/47/EC (the amending MD legislation) and 
applied under the guideline in MedDEV 2.12/1 [42]. 
Under the forthcoming revision of the medical device 
regulation, manufacturers will be subject to more exten-
sive requirements for pre- and post-market assessments, 
especially for high-risk (Class III) devices [43].
Regulation of postmarket modifications to 
combination products in the EU & USA
In the USA, the requirements for making changes 
to a product or its manufacturing process approved 
under a BLA are described in 21 CFR 601.12 
Box 1. Key provisions for a streamlined approach to demonstrating compliance with the current 
Good Manufacturing Practice in 21 Code of Federal Regulation 210/211 or the device Quality System 
Regulations in 21 Code of Federal Regulation 820.
Manufacturers following 21 CFR 210/211
•	 Key provisions of QSR to be implemented:
 – 21 CFR 820.20 Management responsibility
 – 21 CFR 820.30 Design controls
 – 21 CFR 820.50 Purchasing controls
 – 21 CFR 820.100 Corrective and preventive action
 – 21 CFR 820. 170 Installation
 – 21 CFR 820.200 Servicing
Manufacturers following 21 CFR 820
•	 Key provisions of drug GMPs to be implemented:
 – 21 CFR 211.84 Testing and approval/rejection of components, drug product containers and closures
 – 21 CFR 211.103 Calculation of yield
 – 21 CFR 211.132 Tamper-evident packaging for over-the-counter human drug products
 – 21 CFR 211.137 Expiration dating
 – 21 CFR 211.165 Testing and release for distribution
 – 21 CFR 211.166 Stability testing
 – 21 CFR 211.167 Special testing requirements
 – 21 CFR 211.170 Reserve samples
CFR: Code of Federal Regulation; GMP: Good Manufacturing Practice; QSR: Quality System Regulation. 
Data taken with permission from [30–32].
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(Figure 2) [24]. The FDA has developed specific draft 
guidance which outlines the process for determin-
ing which type of submission to provide for a post-
market change to a constituent part of a combina-
tion product under one application (BLA, NDA or 
PMA) [44]. The guideline does not address the type 
or amount of comparability information to include 
in the submission.
In general, all but ‘minor/nonsubstantial’ changes 
require prior approval by the FDA. If the nasal implant 
was filed under a BLA as a combination product for 
example, changes in the biological constituent part or 
design modification to the device part (or changes to 
the production process, quality controls, equipment, 
facilities or responsible personnel) that have substan-
tial potential to adversely affect the critical to qual-
ity attributes (CQAs) of the product as they relate to 
safety and effectiveness would require submission of 
a ‘BLA Prior Approval Supplement’ [44].
In the EU, no such guidance is currently avail-
able, although guidance on post-approval procedures 
to clarify the interaction between the CAT and the 
NB’s for combination products is under development. 
Currently, manufacturers making all but minor post-
approval modifications to the manufacturing pro-
cess (e.g., materials changes, improvements, scale-
up or new facilities), to a constituent part or to the 
combination product as a whole, may require prior 
approval from the EMA under the centralized MA. 
Such amendments may involve changes to the prod-
uct information or changes to the technical dos-
sier submitted by the MA holder. The procedures 
for the approval of such amendments have been set 
out in Regulation (EC) No 1234/2008 [45]. Coor-
dinated by the EMA, this regulation differentiates 
between minor variations (Type IA and Type IB 
variations, e.g., minor quality changes), major varia-
tions (Type II variations, e.g., most manufactur-
ing changes) and certain other major variations in 
the MA (so-called extensions) that necessitate a 
new MA procedure, for example, new indication. 
In addition, ‘significant/substantial’ changes to the 
approved device part or its design that could affect 
the conformity with the Essential Requirements or 
the conditions prescribed for use of the device must 
be approved by the NB according to Annex II and 
III of Directive 93/42/EEC (Figure 2) [17]. This might 
include changes relating to materials or the manu-
facturing process, facility or equipment that have 
the potential to affect the safety and performance of 
the device part. Substantial changes to the manufac-
turer’s approved Quality System are also reportable 
to the NB under Annex II, V and VI of Directive 
93/42/EEC (Figure 2) [17].
Regulatory challenges for 3D-bioprinting 
of customizable advanced combination 
medicinal products
As described earlier, under current EU and USA leg-
islation, cell-based medicinal products in which engi-
neered cells are combined with a material scaffold that 
provides physical support for the growth of new tissue, 
are regulated as biologics in the USA and as combined 
ATMPs in EU. This section considers the hurdles that 
will raise novel challenges for manufacturers of cus-
tomized 3D-bioprinted autologous versions of these 
products under the existing regulatory systems.
Implications for the cell-based combination 
product manufacturer
As described, the USA regulatory system offers manu-
facturers of combination products containing biologic 
and device constituent parts some flexibility in terms 
of how compliance to the varying requirements can 
be achieved. In contrast to the EU, a more adapted 
approval process aims to avoid unnecessary duplication 
and redundancy by providing ways to streamline the 
overlapping aspects of development and the require-
ments for manufacture. Although the regulatory pro-
cess in the USA is not without organizational and 
operational implications for the manufacturer in terms 
of increased quality system costs and longer implemen-
tation times [46], in the EU, where the regulations for 
combination ATMPs appear less flexible as discussed 
below, the implications may be more far reaching.
In the EU, the regulation requires the device compo-
nent to receive a separate license (CE mark) in addition 
to review of the MAA for the cell-based component. 
If the manufacturer of the ATMP also manufactures 
the scaffold or device or if the device component, as an 
integral part of the ATMP, is not manufactured as a 
separate entity (as in this case example), this may create 
a significant regulatory burden for manufacturers. This 
will especially apply to manufacturers of device compo-
nents considered to be Class II or Class III, particularly 
if they are only familiar with one set of the regulations. 
This was the widely perceived view of stakeholders in 
the European Commission’s public consultation on the 
ATMP Regulation in 2012, in which a single assess-
ment process for combined ATMPs was supported to 
reduce uncertainty and avoid potential interpretative 
disparities between different notified bodies (NBs) or 
between the NB and the CAT/CHMP [47,48].
There is a lack of clarity on how regulatory inputs 
for the development of these combination products 
are aligned under the current delineation of the reg-
ulations. There is also uncertainty about the poten-
tial impact on the development and authorization of 
combined ATMPs by the current proposals to amend 
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the medical devices Directives in the EU [43]. This is 
expected to change the role of the NBs and NCAs and 
impose additional requirements for post-marketing 
studies for devices and the materials that may be part 
of them. Under Directive 2001/83/EC [6], the manu-
facturer of the combined ATMP is already subject to 
additional requirements to demonstrate the safety, 
interaction and biocompatibility of all structural com-
ponents. This raises questions about the grounds on 
which the EMA consider evidence of conformity of 
the medical device part sufficient or indeed relevant 
to the role of the device and the evaluation of the com-
bination product as a whole. This especially applies 
to the use of existing data for base materials that have 
been previously deployed in CE marked devices and 
the extent it can be used to support the safety and 
effectiveness assessment. This particularly applies to 
3D-printed product types such as this case example, 
in which the role, form and function of the materials 
used are different to that in the original CE marked 
device and may be changed when printed, during 
post-processing/remodeling or when used in combina-
tion with cellular material. Without such clarity, there 
is potential that the device data requirements could be 
disproportionate to the role of the device in the com-
bined ATMP. This may not lead to better quality prod-
ucts and could confer significant costs and delays in 
marketing approval for some combination products.
Current regulatory environment for 3D-printed 
medicinal products
Additive manufacturing or 3D-printing is an emerging 
production alternative in healthcare enabling manufac-
turers to produce medical products that are accurate 
and precise in geometry and mechanically complex [1]. 
3D-bioprinting allows the design and build of anatomi-
cally matched functional 3D tissue engineered constructs 
by simultaneously placing living cells into defined spatial 
locations within customizable scaffolds using computer-
assisted design and manufacturing models derived from 
CT scans or MRI of the patient’s anatomy. However, 
despite recent progress in bringing 3D-printed medi-
cal devices to clinical use, industrial manufacturers of 
3D-bioprinted tissue engineered combination products 
face many unique scientific and regulatory hurdles that 
result from the ability to create customized products, in 
addition to the challenges that 3D-printing will pose for 
conventional manufacturing paradigms.
As combination products, they are already subject 
to extensive control via implementation of a range of 
legal instruments and an extensive array of technical 
guidance and standards (Figure 2). Manufacturing 
requires regulatory-compliant production facilities 
that have design and device controls and an appropri-
ate clean manufacturing environment. The manufac-
turing process requires a quality system (GMP, QSR). 
Furthermore, the biological process applied to harvest, 
transport and use the biologic material is regulated, 
as are the starting materials as part of the medicinal 
product. The question is how do autologous products 
that are patient-specific (‘batches of one’), made poten-
tially on demand using an industrialized manufactur-
ing process and comprise an integral scaffold or device 
component that can be customizable in the produc-
tion process (and consequently the end result) fit the 
existing regulatory frameworks?
With the potential functional capabilities and limi-
tations of 3D-printing not yet fully understood, there 
is currently no distinct legislation or clear direction 
from regulators regarding the approval of medicinal 
products manufactured using 3D-printing technol-
ogy. However, while a lack of regulatory coverage for 
the safe use of 3D-printed patient-specific devices can 
be seen in the current EU framework, even under the 
new proposals for medical device regulation [43], the 
FDA has set up an additive manufacturing work-
ing group as a path forward, at least for 3D-printed 
medical devices [49]. Supported by the FDA’s labora-
tories for ‘Functional Performance and Device Use’ 
and for ‘Solid Mechanics’, the working group aims 
explore ways of improving the evaluation of custom-
ized 3D-printed devices and to establish parameters 
and standards for materials and other critical product 
safety aspects. Guided by a 2-day additive manufactur-
ing workshop that was held in October 2014 to explore 
the technical challenges associated with 3D-printed 
devices, the FDA has outlined its commitment to 
developing a policy for regulating the additive manu-
facturing field and to creating regulatory guidance on 
3D-printing within the next 2 years [50].
As an established manufacturing method in medi-
cal planning and anatomical modeling 3D-printing 
has already had a transformative effect on hearing aid 
manufacturing [2–4]. The approach has since been used 
to build patient-specific implants and prosthetics in the 
dental, orthopedic and cranio-maxillofacial fields. A 
number of these 3D-printed medical devices have been 
approved by the regulator for emergency or compas-
sionate use in difficult clinical situations [2]. Recently 
however a number of 3D-printed devices have received 
510(k) clearance through the existing medical device 
regulatory pathway in the USA. Oxford Performance 
Materials (OPM) for example, has received 510(k) 
clearances for two 3D-printed devices over the past 
2 years; the OsteoFab Patient-Specific Cranial Device 
(cleared in February 2013) and the OsteoFab Patient-
Specific Facial Device (cleared in July 2014). That the 
predicate devices had not been manufactured using 
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3D-printing did not prevent the FDA from determin-
ing that the new devices were ‘substantially equivalent’ 
to the predicate devices.
This shows that currently there is scope for FDA 
approval of this technology while retaining the abil-
ity to create patient-specific devices without individual 
approval of each item produced. Providing the pro-
cesses can be validated and the specified CQAs and 
performance criteria are conserved, this seems to fit 
3D-printing as a method for mass production of cus-
tomized devices rather than for production of custom-
made devices [51]. In the USA, it therefore appears that 
devices constructed using 3D-printing technology are 
currently subject to the same regulatory review stan-
dards as devices constructed using traditional forma-
tive or subtractive manufacturing practices, in other 
words, based on the equivalence of properties when 
considered as an ‘engineering material’. However, the 
FDA acknowledges that the formal complexity of 
these 3D-printed products is pushing the boundaries 
of current regulatory practice and that further clarity 
on safety and quality control issues will be required to 
match advances in the 3D-printing technology and its 
application to higher risk product categories.
Regulatory considerations for use of 
3D-bioprinting technology to manufacture 
customizable tissue-engineered combination 
products
As defined, the regulatory routes for tissue engineered 
combination products are complex but relatively well 
defined (Figure 2). Howver, they do not address the 
differences between products (or their structural parts) 
manufactured using 3D-printing technology and 
those manufactured using conventional manufactur-
ing techniques. The use of 3D-bioprinting technology 
and the customizable nature of these 3D functional 
living constructs impose constraints on the chemistry, 
manufacturing and control (CMC) elements of their 
development process from design to manufacture and 
add considerable challenges for product quality assur-
ance and testing [1,22,50]. Taking the perspective of a 
manufacturer making both constituent parts in the 
same production facility, the specific areas where exist-
ing EU and USA regulations raise challenges for man-
ufacturers of customized autologous 3D-bioprinted 
tissue engineered products are summarized in Table 1.
The regulatory challenges that surround the adap-
tive manufacturing processing and characterization 
of the autologous cellular component are common to 
all combination products containing engineered cells. 
3D-printing will further challenge these already con-
tested requirements for autologous testing [47,48]. In 
considering 3D co-printing of the nasal implant, the 
different elements within the computer-aided design 
to manufacture chain identify where the specific prod-
uct and process related quality and safety expectations 
differ compared with the situation where device part 
is conventionally manufactured or preformed before 
seeding with living cells. As illustrated in Figure 3, the 
main differences lie in software system chain control 
and the ability to manage and test multiparametric 
and customizable features of the patient-matched 
product (‘batch of one’) as they relate to potential 
variation in the CQAs of the product and the impact 
that these and their interactions may have on product 
performance after surgery. In the following section, 
we examine whether these differences raise new regu-
latory science questions when tested against current 
and emerging regulatory frameworks in the EU and 
the USA.
Specific issues & requirements for process 
validation & control
The customizable nature of 3D-bioprinted products 
means that it is crucial to build a control strategy that 
relies not only on end product testing but also on control 
of starting and raw materials, design control and manu-
facturing process validation (and associated controlling 
software). This will likely require multiparametric and 
risk-based approaches to evaluate the sources of error or 
failure and the relationships between process and build 
parameters and the final product CQA’s. This will help 
establish the critical process parameter limits and con-
trols that should be monitored during the production 
and that when validated will provide assurance of the 
product’s design and build specification at release.
Construction of an accurate solid 3D-printed 
model: specific issues & requirements for 
validating the software system chain
The anatomically matched 3D product is designed and 
built from CAD and CAM models derived from CT 
scans or MRI data using a variety of printing technolo-
gies (Figure 1). This defines the software system chain 
that drives each step in the model construction; the 
software algorithms used to acquire the image of the 
patient’s anatomy, the software algorithms that ana-
lyze and transform (segment out) the image data into 
an accurate digital 3D model, the software algorithms 
that approximate the solid and surface representations 
of the segmented model and the software that applies 
the base model (predefined programming methods, 
setups, machining operations and tool selections), 
updates the customization features of the implant 
according to the surgeon’s specification and drives the 
3D printer system that builds the 3D-printed product 
layer by layer.
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The challenge from a regulatory perspective is to 
design and create optimized microstructures within 
anatomic geometries that can be manufactured and 
individually customized in a reproducible and control-
lable manner so that finished product can be verified 
to meet design control requirements under medical 
device regulations [52]. The interoperability and capa-
bility of the software system chain that drives each step 
therefore needs to be sufficiently robust to reproduce 
accurate models that can be transfigured to achieve the 
specified form, function, formation and fixation char-
acteristics in the final patient-matched product [46]. 
However, there are multiple translation and compila-
tion steps between multiple parameterized software 
applications, each with different error sensitivities. The 
accuracy of the model may be compromised by errors 
or geometric distortions introduced during each of the 
building steps. These may be due to the selection of 
nonoptimal parameters within them, the presence of 
image artifacts, microstructure resolution limitations 
of the printing technology and/or additional errors 
arising from microporosity and anisotropy in the 
microstructure features introduced during the manu-
facturing process [52,53]. Beyond these purely geomet-
ric issues, the propagation of these errors has poten-
tial consequences for the mechanical strength of the 
finished product, the compatibility of the bioprocesses 
that occur within it, for example, cell ingrowth and 
mass transport and even the maintenance of sterility. 
This can lead to differences between the manufactured 
and the designed scaffold.
In terms of image acquisition, the manufacturer will 
need to verify the accuracy and resolution of the ana-
tomic image, accounting for the effects of image arti-
facts and the potential variation between scanners. For 
the digital design, including the dimensional (geomet-
ric shape and its feature) and technical specification 
(tolerance, surface finish, etc.), there may be signifi-
cant regulatory issues related to the CAD-CAM step 
and the use of manual or computer-aided process plan-
ning (CAPP) to translate the design information into 
the process steps and instructions (operation sequence, 
machining parameters, tool setup, QA checkpoints, 
etc.) to manufacture the product. While CAPP sys-
tems are moving toward being generative, they still 
require large amounts of human expertise and manual 
interaction depending on the complexity of the prod-
uct being produced. This applies to the nasal implant 
where the interactions between surface and solid rep-
resentations will affect the complexity of the decision 
rules for process planning, particularly those that 
demand both automated and operator design decisions 
in the customization of the base model to fit the device 
to the patient.
The manufacturer will need to verify that the 
printer controlling software can accurately translate 
the print parameters into the final fabricated product 
(Figure 3). In this regard, optimal design approaches 
can be applied to attain scaffolds with a controlled 
microstructure that have for example, the physical 
properties that balance the often conflicting require-
ments for mechanical rigidity and cell in-growth and 
maintenance that are needed to support regeneration 
(remodeling and bioresorption in vivo) at the implant 
site, while also enabling the flexibility for surgical 
handling. Using 3D-printed prototypes, these com-
putational modeling and simulation approaches can 
be applied to investigate how the design to manufac-
ture chain affects the reproducibility of the optimized 
design characteristics in the final manufactured prod-
uct. For validation purposes (software and hardware), 
being able to relate the design parameters and feature 
sizes from the optimized design to errors, flaws and 
discrepancies propagated in the final manufactured 
structure will be crucial to defining appropriate 
design limits and tolerances, as well as in-process 
and quality controls [52]. This is likely to require 
advances in existing computational design techniques 
to gain greater control over the topographical features 
of the scaffold component. Beyond this, unless the 
3D-printing parameters can be locked in or appro-
priate nondestructive metrology tools are available, 
the manufacturer may need to run a standardized 
test part or analog (with or without surrogate cells) 
to verify that changes, for example to the bioprint-
ing machine (or to different machines), the material 
parameters, the interoperability of different compo-
nent software versions in the system chain or even 
the operator, do not adversely affect the CQAs of the 
finished product.
Specific issues & requirements for assuring 
biocompatibility
Complex 3D geometries and open access microstruc-
tures enabled by 3D-printing create challenges to 
both biocompatibility and sterility. Even if the selected 
3D-printing material is ‘clinically approved’ as part of 
a market approved or CE marked device, the manufac-
turer needs to establish its compatibility with biological 
materials and the printing process [1]. This requires an 
understanding of the effect of the bioprinting process on 
the material as even small changes in the chemical, phys-
ical (structure and degradation) and mechanical proper-
ties can affect the integrity and biocompatibility of the 
structural component and ultimately the performance 
of the finished product when implanted [54].
Equally important are the effects that any product or 
process-related impurities (extractables and leachables) 
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Table 1. Specific areas within the design to manufacture chain where existing EU and USA regulations raise issues 
for manufacturers of customized autologous 3D-bioprinted (co-printed) tissue engineered products. Represents the 
perspective for a manufacturer making both constituent parts in the same production facility.
Specific challenge area Issues
Bridging the regulatory gaps in the development pathway
Combination Product 
Regulations in the EU 
and USA
Lack of harmonization. Different regulatory approval approaches and demands in the USA 
and the EU may increase regulatory burden for manufacturers selling into both markets
Increased compliance costs for quality system implementation, need for highly specialized 
internal skill sets and additional post-marketing requirements for pharmacovigilance and 
comparability assessment especially in the EU
Lack of clarity on how the regulatory inputs are aligned under current delineation of 
regulations in EU. Separate regulatory assessment of medical device and advanced therapy 
medicinal product in EU may create duplication and redundancy
Changes to the manufacturing process (or post-process) or product composition may change 
the way in which these products might be classified and thus the legislation into which the 
product fits, raising questions of borderline status
Limited specific scientific guidelines/standards currently available in EU compared with 
the USA
Persistent issues underpinning regulatory product classification associated with a poor 
understanding of possibly multiple modes of action that contribute to the intended 
therapeutic effect
Current EU medical device regulations may result in interpretative disparities between the 
notified bodies in terms of how devices may be classified, raising questions of borderline 
status
Little clarity on the grounds on which the CAT/CHMP consider evidence of conformity of the 
medical device part sufficient or relevant, particularly where materials have been previously 
deployed in CE marked devices
Uncertainty about the potential impact of the current proposals to amend the medical 
devices Directives in the EU
Uncertainty as to what extent the surgeon may modify the implant in the clinic. Where does 
product regulation end and medical practice begin?
Inherent difficulties in conducting clinical trials for customized products and involving a 
surgical intervention. How to employ a surgical comparator?
Current regulatory framework gives incentives to manufacturers to use medical devices 
already licensed rather than developing new and better targeted devices
Translating 3D-bioprinting to biofabricated product
3D printing technology Currently no distinct legislation, clear direction or guidance from regulators regarding the 
approval of medicinal products manufactured using 3D-printing technology
Differences between the manufactured and the designed scaffold may be introduced by the 
manufacturing process itself and due to resolution limitations of the technology
Interactions with process raw materials and cleaning materials applied to the printer may lead 
to undesirable surface modification
Software, process control and 
validation
Model accuracy may be compromised due to the propagation of errors through multiple 
translation and compilation steps between multiple parameterized software applications in 
order to generate to a process plan and consequently a customized product
Uncertainty about where in system chain software validation is required
Interoperability of different component software versions is uncertain and raises questions 
on re-validation requirements
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or degradation products (e.g., generated in-process 
due to the effects of heat, shear, inadequate line clear-
ance or hold times) have on the cell component during 
manufacture, or post-processing or after implantation. 
If the combination product is manufactured as a single 
entity, whereby live cells are co-printed with a biode-
gradable synthetic polymer rather than seeded into a 
preprinted scaffold, it is not possible to remove leach-
able particles or organics by conventional cleaning or 
extraction approaches. Assurance of biocompatibility 
may therefore take substantial additional resources to 
address unless applicable data have been established for 
use of the material in other approved medical devices, 
for example, PCL has a history of use in long-term 
implantable devices [1].
The manufacturer will need to assess the risk of 
the presence of harmful or toxic impurities and pro-
vide assurance that either the rate or total amount 
of leaching is at an acceptable level once implanted. 
Some conventional toxicity testing of raw materials 
and of the device part alone, using exhaustive extrac-
tion approaches as described in ISO 10993 [55] for 
example, may be necessary before beginning pre-
clinical studies. According to Hollister and Mur-
Specific challenge area Issues
Potential for errors and discrepancies in the design input translation related to the computer-
aided design-computer-aided manufacturing step and the complexity of automated and 
operator decision rules used in the customization of the base model
Limitations of current computational modeling can lead to suboptimal designs and difficulties 
in defining appropriate design limits and tolerances. This has implications for verifying that 
the finished product meets the design inputs
Product and process testing and validation
Chemistry, manufacturing 
and control (CMC) testing of 
the scaffold component
Unless printed analogs (with or without surrogate cells) can be used, co-printed scaffolds can 
only be tested as part of the intermediate and final combination product
Not possible to remove product or process related leachable particles or extractables by 
conventional cleaning or extraction approaches. Biocompatibility testing may require new 
scientific and regulatory approaches
Potential changes to the chemical, physical and mechanical properties of the device material 
and its interaction/compatibility with the cellular part due to the bioprinting process itself
Traditional end sterilization techniques cannot be applied
CMC testing of cells prior to 
assembly
Application of standard cell therapy characterization and test methods is limited by time 
constraints and the amount of material available in the autologous setting
Impact of donor-derived variability on the cell culture manufacturing process and availability 
of seed pool for co-printing
CMC testing of the cell-
scaffold construct
Limited validated methods for characterization and imaging of cells within the intact 
construct, both in vitro and in situ after implantation
Full characterization and testing of the final product is hindered by time and sampling 
constraints related to lot size (‘batch of one’) and potential for manufacture on demand
Construct may not be in its final form when administered to patients as in vivo remodeling 
can occur. In this case, any final product specifications determined through in vitro testing 
may not be predictive of clinical safety and efficacy
Difficult to define potency/performance requirements and specifications because they will be 
specific to the patient and the intended use likely to involve multiple modes of action
May not be possible to sample and detect adventitious agents that may be retained deep 
within potentially complex internal porous microstructures
Lack of appropriately validated nondestructive metrology tools and standards to address the 
inspection of physical, geometric and mechanical properties that are specific to the product 
type and its intended use
Increased production costs attributed to the requirement for multiple levels quality control 
throughout the manufacturing process
Table 1. Specific areas within the design to manufacture chain where existing EU and USA regulations raise issues 
for manufacturers of customized autologous 3D-bioprinted (co-printed) tissue engineered products. Represents the 
perspective for a manufacturer making both constituent parts in the same production facility (cont.).
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phy, these tests could cost between US$0.5 and 3 
million [46]. Otherwise, testing may have to rely on 
the long-term biocompatibility studies to detect the 
effects of the structural component on cellular behav-
ior and survival (e.g., cell adhesion studies, growth 
studies) and assess the potential for an adverse bio-
logical reaction to occur as a result of exposure to the 
material once the final product is implanted, perhaps 
via a conditional adaptive or accelerated licensing 
process.
Specific issues & requirements for assuring 
sterility
The control strategy aims to show the ability to repro-
ducibly manufacture a safe product that is sterile 
and free of unwanted contaminants. Where it is not 
possible to sterilize the end product, sterility assur-
ance processes become a function of the starting and 
raw materials, the cleaning processes applied to the 
3D-printing machine between runs, the solid and sur-
face microstructures within the geometries of the fin-
ished product and environmental conditions in which 
the bioprinting and any post-processing takes place.
In the case of the nasal implant, like all cell-based 
products the maintenance of sterility is important 
throughout the entire process. Of particular concern 
would be the ability to sample and detect adventitious 
agents that may be retained deep within potentially 
complex internal porous microstructures, which may 
not be reachable by the immune system and that 
could be released as the material degrades in vivo. 
The manufacturer may need to apply conventional 
risk-based bracketing designs to sterility testing, such 
that analogs of the device part can be tested at the 
minimum and maximum tolerance limits for features 
such as internal and surface porosity or other critical 
design parameters, accounting also for in vivo biofilm 
forming capability which may create routes of infec-
tion once implanted [50].
Specific issues & requirements for product 
validation & release: how much testing is 
required?
When considering design control, validation and 
release testing for products that are both patient-
matched (‘batches of one’) and made potentially on 
demand, complete characterization of the finished 
product that may or may not (where in vivo remod-
eling can occur) be in its final form when implanted 
into the patient is unlikely to be possible. Beyond opti-
mal design for manufacturing approaches, this places 
greater emphasis on more extensive preclinical and 
in vivo safety testing, in-process controls and the use 
of other adaptive approaches to providing sufficient 
information on risk versus benefit.
Broadly, there are three groups of metrics that will 
likely define the registered specification on which 
market authorization for these types of customized 
implants will be based. These relate to the bulk prop-
erties, the surface properties and the critical dimen-
sions of the product. Sufficient evidence will be needed 
to verify that the final product will perform to the 
required standards within the range that these met-
rics may cover alone or in combination. In the case of 
the prosthetic nose for example, the following physical 
and patient-matched parameters are some of the criti-
cal metrics that may serve as a basis for a testing and 
validation strategy:
•	 Bulk properties: the infrastructure, whether homo- 
or heterogeneous, will need to be validated for the 
mass transport necessary for cell maintenance and 
Figure 3. Simplified diagram of the design to manufacture chain for the production of the 3D co-printed nasal 
implant product. Indicates the key decision processes (highlighted in red) that influence the solid and surface 
representations of the 3D model and introduce downstream risk points (arrows) to the production of the finished 
product. The decision processes and associated risk points indicate the processing and post-processing activities of 
concern to product quality and safety from a regulatory perspective.  
CAD: Computer-aided design; CQA: Critical to quality attribute; QP: Qualified person.
O
ut
co
m
es
In
te
gr
at
io
n
S
ur
ge
on
im
pl
an
ts
S
ur
ge
on
fin
is
he
s
In
sp
ec
tio
n
(Q
P
)
M
at
ur
at
io
n
In
te
rm
ed
ia
te
3D
 p
rin
te
r
T
oo
l p
at
h
C
A
D
 m
od
el
Im
ag
in
g
Surface
Solid
Decisions
(operator and automated)
CQA CQA CQA CQA CQA
www.futuremedicine.com 17future science group
Regulatory requirements for 3D bioprinting    Review
remodeling rates in vivo in order to ensure struc-
tural integrity and long-term patient outcomes. 
This will require the solid mechanics that describe 
how the scaffold construct responds to the stresses 
associated with the product’s intended use com-
pared with the native tissue it aims to replace. For 
example, considering that tissue engineered nasal 
structures are prone to postoperative contraction 
and may even develop contractile behavior during 
the in vitro maturation process, it will be important 
to evaluate the influence of the fabrication process 
on the stability of the intermediate and final tissue 
engineered implants;
•	 Surface properties: edge effects that may occur due 
to the printing technique may need to be either cor-
rected or allowed for in manufacturing or preim-
plant finishing activities by the surgeon. The latter 
requires assurance that activities in the clinic do not 
compromise the interface between patient and pros-
thetic, taking into account the number, location and 
local properties of any specific regions that are built 
into the prosthetic design solely to provide anchor 
points or eyelets for surgical fixation. This raises the 
question as to what extent the surgeon may modify 
the implant in clinic? The postimplant environment 
must be conducive to integration if necrosis is to be 
avoided. Consequently, the preimplant finishing 
activities will need to occur within a prescribed scope 
if the prosthetic performance is to be maintained;
•	 Critical dimensions: there will be a limit to the 
dimensions over which perfusion and tissue migra-
tion can occur without being explicitly addressed 
by the design of the nasal implant, for example, by 
the provision of blood flow or angiogenesis. These 
will need to be established, in particular the limits 
to effective vascularization must be determined as a 
function of distance for the prosthetic bulk proper-
ties, accounting for variations that may occur due 
to the patient’s health and age.
With many different physical and patient-matched 
design parameters and permutations, approaches 
to defining product and process validation strate-
gies may need to rely on improved multiparametric 
computational modeling and simulation method-
ologies, applied to enhance process knowledge and 
image analysis for example. Sampling and quality 
inspection routines, to support parametric release, 
for example, are likely to require the manufacture of 
extra predefined analog units of known dimension, 
void volume and other critical physical features that 
can be tested within statistically designed bracket-
ing and matrixing test regimes. Even at the dimen-
sional level, such inspection methods, as well as those 
applied within process and to the finished product, 
will need to be underpinned by the availability of 
applicable and validated nondestructive test systems 
(from the perspective of both constituent parts) and 
the development of associated industry standards and 
guidance. Despite recent progress [56], this is likely 
to require further advances in the development of 
validated methods for characterization, tracking and 
imaging of cells within the intact construct, both 
in vitro and in situ after implantation.
Conclusion
This paper highlights the importance of defining the 
characteristics and features of the development process 
and the finished product to identifying and understand-
ing where the regulatory legislation might apply across 
each stage of the development pathway. Careful exami-
nation of the existing regulatory paths in the EU and 
the USA emphasizes that combining synthetic scaffolds 
with cultured human cells creates a combination medic-
inal product that will command a high level of regu-
latory scrutiny, particularly for the manufacturer that 
makes both constituent parts. Despite recent success 
in bringing 3D-printed medical devices to clinical use, 
the existing regulatory frameworks do not adequately 
account for aspects related to the use of computer-aided 
3D-bioprinting as an industrial manufacturing process 
with the ability to create individual customized tissue 
engineered combination products using mechanized 
rather than craft approaches, which are typically easier 
to validate. In considering the hypothetical exemplar of a 
customized, autologous 3D-printed combination prod-
uct, the major regulatory concerns and hence the chal-
lenges for the manufacturer are likely to resonate most 
in the process from design to manufacture, in terms of 
the software system chain control and validation, the 
potential variation in CQAs of the final manufactured 
product, such as mechanical stiffness and strength, bio-
compatibility and sterility and the consequent impact 
on product performance after surgery.
Beyond the scientific and technical challenges [1], if 
3D-bioprinting is to achieve its promissory vision and 
expectations, new and proportionate regulatory science 
approaches are likely be required to address concerns 
that surround aspects related to how these customiz-
able product types can be tested and validated. In the 
meantime, with little or no scientific guidance available, 
if the field is to move forward the research and develop-
ment community will need early and regular dialogue 
with regulatory agencies at particular translational 
bottlenecks in the manufacturing and quality devel-
opment process. We anticipate that key areas that will 
require focus are product and process characterization, 
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in particular validation that the printing process plan 
has delivered a consistent and viable tissue.
Future perspective
In the EU, the regulatory ambiguity in Regenerative 
Medicine significantly impacted the field until the 
implementation of the regulation on ATMPs (Regula-
tion (EC) No 1394/2007) by the European Commis-
sion at the beginning of 2009. Along with impending 
changes to the medical device directive and revision 
to the EU clinical trials framework in 2016, further 
refinement can be expected in the ATMP Regulation 
in the near future. In the USA, with medical device 
reforms and clarification of the regulations for combi-
nation products under the 21st Century Cures legisla-
tion, the FDA is also expected to release further guid-
ance for combination products and for 3D printing. 
These changes are likely to address a number of regula-
tory gaps that exist for combination products but it is 
unclear whether they will sufficiently address some of 
the shortcomings the industry is facing when it comes 
to 3D bioprinting of customizable combination prod-
ucts or how the regulations will differ between the two 
regions.
Linked to the current FDA activity in the USA, there 
is a requirement to escalate the need for proportionate 
regulation of medicinal products that are customizable 
to individuals using an ‘industrial process’ that has a 
significant software component. If expectations around 
the 3D-bioprinting field are to materialize, action needs 
to take account of the momentum of clinical demand 
and the application ambitions in the field. New value 
and business models are likely to emerge linked to the 
need for different organizational and development mod-
els and for new medical professionals (next-generation 
prosthetists) to bridge the regulatory gap for customized 
combination product manufacturers.
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Executive summary
Regulation of cell-scaffold products under existing frameworks
•	 The classification of the product defines the regulatory route in the USA and the EU. Where living cells are 
physically combined with a synthetic scaffold matrix to create a finished medicinal product, the product can 
be classified as a combination product: if the cells are viable; if the cells have been substantially or more than 
minimally manipulated; if the cells do not carry out the same function in the recipient as the donor; if the 
scaffold is an integral part of the finished product; if the scaffold meets the definition of a medical device.
•	 As defined, where the primary or principal mode of action is provided by the cellular constituent part, these 
combination products are regulated as biologics in the USA and as a Combined Tissue Engineered advanced 
therapy medicinal products in the EU (if mode of action is regeneration and repair of a human tissue).
•	 Unlike in the EU, in USA combination products are regulated as a distinct product category and the US FDA 
have issued specific rules and guidance that streamlines the regulatory route for Good Manufacturing 
Practice, adverse event reporting and for making postmarket approval changes
Regulation of customizable tissue engineered combination products manufactured using 3D-bioprinting 
technology
•	 As defined, the existing regulatory frameworks do not account for aspects related to customization or to 
differences between products manufactured using 3D-printing technology and those where the device part is 
manufactured conventionally.
•	 The main difference between customized implants co-printed with living cells and tissue engineered 
constructs where the device part (scaffold) is preformed prior to seeding with living cells lies in the computer-
aided design to manufacture process. Specific regulatory challenges relate to software system chain control 
and the ability to manage and test multiparametric and customizable features of the product as they relate 
to potential variation in critical to quality attributes of the product and the impact that these and their 
interactions may have on product performance after surgery.
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